Lamellar Biomedical Secures Its First Orphan Drug Licence
Originally posted in Cystic Fibrosis News From Medical News Today
Glasgow biopharmaceutical firm, Lamellar Biomedical Ltd, launched four years ago to develop a new class of therapies for the prevention, treatment and control of severe respiratory disease, today announced that their lead clinical candidate LMS-611 for the treatment of patients with cystic fibrosis has received Orphan Drug Designation from the European Commission…
No Comments »
RSS feed for comments on this post. TrackBack URL
by Raelene
